紫杉醇脂质体联合改良FOLFOX方案对胃癌术后复发的疗效观察

摘要

Objective To evaluate the clinical efficacy of paclitaxel liposome combined with FOLFOX improvement plan (oxaliplatin + tegafur+calcium folinate) in the treatment of the recurrence of gastric cancer after curative resection.Methods A retrospective analysis was done of 95 cases from the general surgery department from January 2013 to June 2016,with 45 cases (patients) adopting the treatment of tegafur,and the other 50 the treatment of paclitaxel liposome with FOLFOX with a 21-day period.After four periods,the efficacy of the two treatments were compared.Results For the tegafur group,no complete remission cases were observed,and partial remission was observed in 13 cases,stable disease in 18 and progressive disease in 14.The effective rate was 28.9％,and the progression free survival was 5.7 months.For the second group,no complete remission was observed in the patients,partial remission in 16 cases,stable disease in 23 and progressive disease in 11.The effective rate was 32.0％ and the progression free survival was 7.8 months.No significant difference was found between the two groups in effective rate (P ＞ 0.05),but the progression free survival ofpaclitaxel liposome with modified FOLFOX regimen was significantly longer than that of the tegafur (P ＜ 0.05).Conclusion Paclitaxel liposome with modified FOLFOX regimen was effective in treating patients with the recurrence of gastric cancer after curative resection,and it can be used as a second-line chemotherapy.%目的 评价紫杉醇脂质体联合改良FOLFOX方案(奥沙利铂+替加氟+亚叶酸钙)对胃癌术后复发的临床疗效.方法 回顾性分析收治的95例进行胃癌根治性手术后复发的患者,其中45例患者采用口服替吉奥,50例患者采用紫杉醇脂质体联合改良FOLFOX方案.21d为1个治疗周期,治疗4个周期后评价2组患者治疗的临床疗效.结果 采用替吉奥的45例患者中,完全缓解0例,部分缓解13例,病情稳定18例,病情进展14例,有效率为28.9％,无进展生存期5.7个月;采用紫杉醇脂质体联合改良FOLFOX方案的50例患者中,完全缓解0例,部分缓解16例,病情稳定23例,病情进展11例,有效率为32.0％,无进展生存期7.8个月.比较2组有效率差异无统计学意义(P＞ 0.05);采用紫杉醇脂质体联合改良FOLFOX方案的无进展生存期较替吉奥化疗方案明显延长,差异有统计学意义(P＜0.05).结论 紫杉醇脂质体联合改良FOLFOX方案对胃癌术后复发的近期疗效尚可,可作为二线方案使用.